Results 121 to 130 of about 1,479,071 (353)

Patient Reported Outcome Measures: Challenges in the Reporting!

open access: yesAnnals of Surgery Open, 2021
Melissa N. Orr, BS   +2 more
doaj   +1 more source

Development and validation of clinical implementation methods for patient-reported outcomes in Japanese multi-center palliative care units

open access: yesJournal of Patient-Reported Outcomes
Background Patient-Reported Outcomes (PROs) are recommended for use in clinical oncology. However, they are not routinely used in professional palliative care practices in Japan.
Nao Ito   +6 more
doaj   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook   +6 more
wiley   +1 more source

Developing a set of patient‐centered outcomes for routine use in endometriosis: An international Delphi study

open access: yesActa Obstetricia et Gynecologica Scandinavica
Introduction There is large variation in individual patient care for endometriosis. A uniform approach to measure outcomes could be incorporated into routine clinical practice to personalize and monitor treatments and potentially improve the quality of ...
Alba Nicolas‐Boluda   +6 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta   +6 more
wiley   +1 more source

Korean Translation and Psychometric Properties of Self-Report Instrument for Mobility Measuring for Adults With Lower Limb Amputation [PDF]

open access: yesAnnals of Rehabilitation Medicine
Objective To assess mobility in prosthetic limb users, the Prosthetic Limb Users Survey of Mobility (PLUS-M) was developed as a brief item bank. The PLUS-M exhibits good reliability and has been translated into more than 15 languages; however, a Korean ...
Jin Hong Kim, Sohye Jo, Gangpyo Lee
doaj   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

Routine use of patient-reported experience and outcome measures for children and young people: a scoping review

open access: yesSystematic Reviews
Background Patient-reported outcome measures (PROMs) measure people’s views of their health status whereas patient-reported experience measures (PREMs) are questionnaires measuring perceptions of their experience whilst receiving healthcare.
Anne Alarilla   +8 more
doaj   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy